2/20/2013

GlaxoSmithKline and Theravance said the FDA has accepted their new drug application for Anoro as a daily treatment for chronic obstructive pulmonary disease. Anoro, formerly known as UMEC/VI, is a combination of umeclidinium bromide, a long-acting muscarinic antagonist, and vilanterol, a long-acting beta-2 agonist. The FDA is expected to decide by Dec. 18.

Related Summaries